Strattera (Atomoxetine) FAQs: Mastering ADHD Treatment Without Stimulants

Strattera is primarily used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults.

Strattera increases the levels of norepinephrine, a neurotransmitter in the brain, which helps improve attention span, concentration, and reduces impulsivity and hyperactivity in individuals with ADHD.

No, Strattera is not a stimulant. It is a selective norepinephrine reuptake inhibitor (SNRI), making it an alternative to stimulant medications for ADHD.

It may take several weeks to see improvements in ADHD symptoms. Some individuals might start noticing benefits within 2-4 weeks, but it can take up to 6-8 weeks for full effects.

Common side effects include stomach upset, nausea, vomiting, decreased appetite, dizziness, tiredness, and mood swings.

Strattera can interact with certain medications, so it's important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs.

Yes, Strattera has been proven effective in treating ADHD symptoms in adults as well as in children and adolescents.

Yes, decreased appetite and weight loss are possible side effects of Strattera, especially in the initial stages of treatment.

Yes, Strattera is a prescription medication and should be used under the guidance of a healthcare provider.

Strattera is taken orally, once or twice daily, with or without food. It's important to follow your healthcare provider's instructions regarding dosage and timing.

Some individuals may experience insomnia or sleep disturbances when taking Strattera. Taking it in the morning may help minimize this effect.

No, Strattera is not considered addictive and has no known potential for abuse, making it an option for individuals concerned about these issues with stimulant medications.

While Strattera does not typically produce withdrawal symptoms, it's important to consult with a healthcare provider before making any changes to the dosage or discontinuing the medication.

If you miss a dose, take it as soon as you remember, but if it's close to the time of your next dose, skip the missed dose. Do not double up doses.

Yes, one of the primary benefits of Strattera is improved concentration and focus in individuals with ADHD.

In some cases, healthcare providers may prescribe Strattera in combination with stimulant medications, but this should only be done under professional supervision.

Strattera is not a controlled substance and is unlikely to show up on standard drug screening tests.

Mood swings and emotional instability are possible side effects, particularly in the initial phase of treatment.

The safety of Strattera during pregnancy is not well established. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

In rare cases, Strattera has been associated with liver damage. Alert your healthcare provider if you experience symptoms such as yellowing skin/eyes, dark urine, or severe abdominal pain.

Store at room temperature away from moisture and heat. Keep the medication in a secure place out of reach of children.

Strattera may impact growth and weight in some children. Healthcare providers may monitor growth during treatment.

Coverage varies by insurance plan. Check with your insurance provider to determine if Strattera is covered under your plan.

Yes, some individuals may experience sexual side effects, including decreased libido or difficulty achieving orgasm.

Combining alcohol with Strattera can increase the risk of liver damage and may worsen certain side effects. Discuss alcohol use with your healthcare provider.

While not primarily indicated for anxiety, some individuals with ADHD may notice an improvement in anxiety symptoms due to overall improvements in ADHD symptoms.

There is a warning that children and adolescents taking Strattera may have an increased risk of suicidal thoughts. Patients should be monitored for any signs of depression or suicidal thoughts, especially during the initial months of treatment or when doses are adjusted.

Unlike stimulant medications, Strattera does not have a risk of abuse or dependence and works by selectively inhibiting norepinephrine reuptake, offering a different mechanism of action for treating ADHD.

Strattera can cause an increase in heart rate and blood pressure. These vital signs should be monitored during treatment.

In case of overdose, seek immediate medical attention. Symptoms of an overdose may include drowsiness, dizziness, tremors, or abnormal behavior.

Combining Strattera with other non-stimulant ADHD medications should be done under the guidance of a healthcare provider to avoid potential interactions.

Long-term effects can include sustained improvement in ADHD symptoms. However, healthcare providers may periodically evaluate the need for ongoing treatment.